{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:03:45Z","timestamp":1787828625698,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011665","name":"Deanship of Scientific Research, King Saud University","doi-asserted-by":"publisher","award":["ORF-2025-853"],"award-info":[{"award-number":["ORF-2025-853"]}],"id":[{"id":"10.13039\/501100011665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Saudi Pharm. J."],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s44446-026-00072-4","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:35:39Z","timestamp":1771922139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Discovery of a novel VEGFR2 inhibitor using integrated structure-based docking study and functional validation: potential applications in targeted cancer therapy"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5544-9177","authenticated-orcid":false,"given":"Hussam","family":"Albassam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Alobid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Altowairqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"30","key":"72_CR1","doi-asserted-by":"publisher","first-page":"21668","DOI":"10.1039\/d4ra03459g","volume":"14","author":"HH Bayoumi","year":"2024","unstructured":"Bayoumi HH, Ibrahim M-K, Dahab MA, Khedr F, El-Adl K (2024) Exploration of the VEGFR-2 inhibition activity of phthalazine derivatives: design, synthesis, cytotoxicity, ADMET, molecular docking and dynamic simulation. RSC Adv 14(30):21668\u201321681. https:\/\/doi.org\/10.1039\/d4ra03459g","journal-title":"RSC Adv"},{"issue":"2","key":"72_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11912-011-0154-3","volume":"13","author":"P Bhargava","year":"2011","unstructured":"Bhargava P, Robinson MO (2011) Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep 13(2):103\u2013111. https:\/\/doi.org\/10.1007\/s11912-011-0154-3","journal-title":"Curr Oncol Rep"},{"issue":"6835","key":"72_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/35077225","volume":"411","author":"P Blume-Jensen","year":"2001","unstructured":"Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411(6835):355\u2013365. https:\/\/doi.org\/10.1038\/35077225","journal-title":"Nature"},{"issue":"W1","key":"72_CR4","doi-asserted-by":"publisher","first-page":"W324","DOI":"10.1093\/nar\/gkae300","volume":"52","author":"M Bugnon","year":"2024","unstructured":"Bugnon M, R\u00f6hrig UF, Goullieux M, Perez MAS, Daina A, Michielin O, Zoete V (2024) SwissDock 2024: major enhancements for small-molecule docking with Attracting Cavities and AutoDock Vina. Nucleic Acids Res 52(W1):W324\u2013W332. https:\/\/doi.org\/10.1093\/nar\/gkae300","journal-title":"Nucleic Acids Res"},{"key":"72_CR5","doi-asserted-by":"publisher","unstructured":"Dallakyan S, Olson AJ (2015) Small-Molecule Library Screening by Docking with PyRx. In J. E. Hempel, C. H. Williams, C. C. Hong (Eds.), Chemical Biology (Vol. 1263, pp. 243\u2013250). Springer New York. https:\/\/doi.org\/10.1007\/978-1-4939-2269-7_19","DOI":"10.1007\/978-1-4939-2269-7_19"},{"issue":"1","key":"72_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13321-018-0283-x","volume":"10","author":"J Dong","year":"2018","unstructured":"Dong J, Wang N-N, Yao Z-J, Zhang L, Cheng Y, Ouyang D, Lu A-P, Cao D-S (2018) ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. J Cheminform 10(1):29. https:\/\/doi.org\/10.1186\/s13321-018-0283-x","journal-title":"J Cheminform"},{"issue":"18","key":"72_CR7","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1002\/cncr.25333","volume":"116","author":"T Donnem","year":"2010","unstructured":"Donnem T, Al-Shibli K, Andersen S, Al-Saad S, Busund L-T, Bremnes RM (2010) Combination of low vascular endothelial growth factor A (VEGF-A)\/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer 116(18):4318\u20134325. https:\/\/doi.org\/10.1002\/cncr.25333","journal-title":"Cancer"},{"issue":"1","key":"72_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejca.2005.09.018","volume":"42","author":"SE Duff","year":"2006","unstructured":"Duff SE, Jeziorska M, Rosa DD, Kumar S, Haboubi N, Sherlock D, O\u2019Dwyer ST, Jayson GC (2006) Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer 42(1):112\u2013117. https:\/\/doi.org\/10.1016\/j.ejca.2005.09.018","journal-title":"Eur J Cancer"},{"issue":"12","key":"72_CR9","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.humpath.2008.06.004","volume":"39","author":"S Ghosh","year":"2008","unstructured":"Ghosh S, Sullivan CAW, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL, Chung GG (2008) High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 39(12):1835\u20131843. https:\/\/doi.org\/10.1016\/j.humpath.2008.06.004","journal-title":"Hum Pathol"},{"issue":"21","key":"72_CR10","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1042\/BCJ20200702","volume":"477","author":"M Gonzalez-Magaldi","year":"2020","unstructured":"Gonzalez-Magaldi M, McCabe JM, Cartwright HN, Sun N, Leahy DJ (2020) Conserved roles for receptor tyrosine kinase extracellular regions in regulating receptor and pathway activity. Biochem J 477(21):4207\u20134220. https:\/\/doi.org\/10.1042\/BCJ20200702","journal-title":"Biochem J"},{"issue":"Web Server issu","key":"72_CR11","doi-asserted-by":"publisher","first-page":"W270","DOI":"10.1093\/nar\/gkr366","volume":"39","author":"A Grosdidier","year":"2011","unstructured":"Grosdidier A, Zoete V, Michielin O (2011) SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 39(Web Server issue):W270-277. https:\/\/doi.org\/10.1093\/nar\/gkr366","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"72_CR12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1128\/JVI.9.5.800-803.1972","volume":"9","author":"JC Kaplan","year":"1972","unstructured":"Kaplan JC, Wilbert SM, Black PH (1972) Endonuclease activity associated with purified simian virus 40 virions. J Virol 9(5):800\u2013803. https:\/\/doi.org\/10.1128\/JVI.9.5.800-803.1972","journal-title":"J Virol"},{"issue":"4","key":"72_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13009","volume":"54","author":"G Liu","year":"2021","unstructured":"Liu G, Chen T, Ding Z, Wang Y, Wei Y, Wei X (2021) Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. Cell Prolif 54(4):e13009. https:\/\/doi.org\/10.1111\/cpr.13009","journal-title":"Cell Prolif"},{"issue":"4","key":"72_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.6004\/jadpro.2013.4.4.7","volume":"4","author":"AM McDonnell","year":"2013","unstructured":"McDonnell AM, Dang CH (2013) Basic review of the cytochrome p450 system. J Adv Pract Oncol 4(4):263\u2013268. https:\/\/doi.org\/10.6004\/jadpro.2013.4.4.7","journal-title":"J Adv Pract Oncol"},{"issue":"3","key":"72_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.humpath.2009.08.016","volume":"41","author":"JM Mehnert","year":"2010","unstructured":"Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM (2010) Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 41(3):375\u2013384. https:\/\/doi.org\/10.1016\/j.humpath.2009.08.016","journal-title":"Hum Pathol"},{"issue":"34","key":"72_CR16","doi-asserted-by":"publisher","first-page":"36245","DOI":"10.18632\/oncotarget.5768","volume":"6","author":"MB Morelli","year":"2015","unstructured":"Morelli MB, Amantini C, Santoni M, Soriani A, Nabissi M, Cardinali C, Santoni A, Santoni G (2015) Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. Oncotarget 6(34):36245\u201336259. https:\/\/doi.org\/10.18632\/oncotarget.5768","journal-title":"Oncotarget"},{"issue":"2","key":"72_CR17","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.18632\/oncotarget.13769","volume":"8","author":"MB Morelli","year":"2017","unstructured":"Morelli MB, Amantini C, Nabissi M, Cardinali C, Santoni M, Bernardini G, Santoni A, Santoni G (2017) Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: the proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf\/Cip1) dependent manner. Oncotarget 8(2):3380\u20133395. https:\/\/doi.org\/10.18632\/oncotarget.13769","journal-title":"Oncotarget"},{"issue":"5","key":"72_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrm1911","volume":"7","author":"A-K Olsson","year":"2006","unstructured":"Olsson A-K, Dimberg A, Kreuger J, Claesson-Welsh L (2006) VEGF receptor signalling\u2014in control of vascular function. Nat Rev Mol Cell Biol 7(5):359\u2013371. https:\/\/doi.org\/10.1038\/nrm1911","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6398","key":"72_CR19","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/359845a0","volume":"359","author":"KH Plate","year":"1992","unstructured":"Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359(6398):845\u2013848. https:\/\/doi.org\/10.1038\/359845a0","journal-title":"Nature"},{"issue":"12","key":"72_CR20","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1021\/acs.jcim.3c00054","volume":"63","author":"UF R\u00f6hrig","year":"2023","unstructured":"R\u00f6hrig UF, Goullieux M, Bugnon M, Zoete V (2023) Attracting cavities 2.0: improving the flexibility and robustness for small-molecule docking. J Chem Inf Model 63(12):3925\u20133940. https:\/\/doi.org\/10.1021\/acs.jcim.3c00054","journal-title":"J Chem Inf Model"},{"issue":"1","key":"72_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"72_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1517\/14728222.7.2.215","volume":"7","author":"P Traxler","year":"2003","unstructured":"Traxler P (2003) Tyrosine kinases as targets in cancer therapy\u2014successes and failures. Expert Opin Ther Targets 7(2):215\u2013234. https:\/\/doi.org\/10.1517\/14728222.7.2.215","journal-title":"Expert Opin Ther Targets"},{"key":"72_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1196\/annals.1322.019","volume":"1028","author":"C Tsatsanis","year":"2004","unstructured":"Tsatsanis C, Spandidos DA (2004) Oncogenic kinase signaling in human neoplasms. Ann N Y Acad Sci 1028:168\u2013175. https:\/\/doi.org\/10.1196\/annals.1322.019","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"72_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23040747","volume":"23","author":"N Wei","year":"2018","unstructured":"Wei N, Liang J, Peng S, Sun Q, Dai Q, Dong M (2018) Design, synthesis, and biological evaluation of Axitinib derivatives. Molecules 23(4):747. https:\/\/doi.org\/10.3390\/molecules23040747","journal-title":"Molecules"},{"issue":"4","key":"72_CR25","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0022-5347(05)00736-6","volume":"175","author":"G Xia","year":"2006","unstructured":"Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, Zhu S, Masood R, Quinn DI, Broek D, Stein JP, Gill PS (2006) Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 175(4):1245\u20131252. https:\/\/doi.org\/10.1016\/S0022-5347(05)00736-6","journal-title":"J Urol"},{"issue":"4","key":"72_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/jcc.24249","volume":"37","author":"V Zoete","year":"2016","unstructured":"Zoete V, Schuepbach T, Bovigny C, Chaskar P, Daina A, R\u00f6hrig UF, Michielin O (2016) Attracting cavities for docking. Replacing the rough energy landscape of the protein by a smooth attracting landscape. J Comput Chem 37(4):437\u2013447. https:\/\/doi.org\/10.1002\/jcc.24249","journal-title":"J Comput Chem"}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44446-026-00072-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44446-026-00072-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44446-026-00072-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T19:31:38Z","timestamp":1772739098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44446-026-00072-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["72"],"URL":"https:\/\/doi.org\/10.1007\/s44446-026-00072-4","relation":{},"ISSN":["1319-0164","2213-7475"],"issn-type":[{"value":"1319-0164","type":"print"},{"value":"2213-7475","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was unnecessary for this research, as it involved only commercially available established cell lines, adhering to local legislation and institutional guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors report there are no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"8"}}